Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE) At Week 48, more individuals receiving DZP experienced no or low disease activity compared to standard of care with differences observed as early as Week 12BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) — UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe...

SIKA IS UNLOCKING SMART AND DURABLE SOLUTIONS FOR DATA CENTER CONSTRUCTION Today in Dallas, United States, Sika outlines strategic initiatives and high-performance solutions that will drive the future of data center construction. With over 1,000 data centers built using Sika solutions and a strong pipeline of new projects, Sika has become the trusted partner of technology leaders shaping digital infrastructure worldwide. Global investments in data centers are projected to exceed CHF 400 billion by 20281, driven by the surging demand for cloud computing, artificial intelligence, and the Internet of Things (IoT). With the launch of the Stargate project alone, CHF 410 billion will be invested additionally in the United States over the next four years to develop data centers and infrastructure for training and operating advanced AI systems....

May was a stable month for Bigbank – both the loan and deposit portfolios grew at a steady pace, and profitability remained at a solid level. The loan portfolio increased by a total of 43 million euros in May. The largest contributions came from business loans and home loans, which grew by 22 million and 15 million euros, respectively. The consumer loan portfolio grew by 6 million euros. The deposit portfolio grew by a total of 26 million euros in May. In a declining interest rate environment, the savings deposit product became more attractive to customers, with its portfolio increasing by 18 million euros during the month. The term deposit portfolio also returned to growth, increasing by 8 million euros. It is encouraging that despite falling interest rates, Bigbank has increased its net interest income during the first five months of...

TORONTO, June 12, 2025 (GLOBE NEWSWIRE) — Critical One Energy Inc. (formerly Madison Metals Inc.) (“Critical One” or the “Company”) (CSE: CRTL) (OTCQB: MMTLF) (FSE: 4EF0) is pleased to announce that Dark Star Minerals Inc. (“Dark Star”) (CSE: BATT) (FSE: P0W), a well-managed, uranium-focused, publicly-listed company, has entered into an acquisition agreement with Critical One to acquire 100% of its interests in the Khan and Cobra Uranium Projects, located in Namibia’s highly prospective Erongo uranium province. “Divesting the Company’s uranium assets and focusing on the Howells Lake Antimony-Gold Project (“Howells Lake Project”) enhances our shareholder value by strategically refining the Company’s critical metals and minerals mission,” said Duane Parnham, Executive Chairman and CEO of Critical One. “I believe this shift in our...

MONTREAL, June 11, 2025 (GLOBE NEWSWIRE) — Osisko Development Corp. (NYSE: ODV, TSXV: ODV) (“Osisko Development” or the “Company“) announces the filing of a technical report (the “Technical Report“) prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101“) in respect of the feasibility study (“2025 FS“) for its permitted, 100%-owned Cariboo Gold Project (the “Cariboo Gold Project“), located in central British Columbia, Canada. The Technical Report, titled “NI 43-101 Technical Report, Feasibility Study for the Cariboo Gold Project, District of Wells, British Columbia, Canada” and dated June 11, 2025 (with an effective date of April 25, 2025), was prepared in accordance with NI 43-101 by independent...

VANCOUVER, British Columbia, June 11, 2025 (GLOBE NEWSWIRE) — Mustang Energy Corp. (CSE: MEC, OTC:MECPF, FRA:92T) (the “Company” or “Mustang”) is pleased to announce that it has initiated an Aerial Electromagnetic Survey (Xcite™ TDEM) with Radiometrics over the Spur Project (the “Project”) located south of the Athabasca Basin, Saskatchewan. The Project is located in a favorable region prospective for uranium, rare earth elements (REEs), and base metal mineralization. The Xcite™ TDEM survey with Radiometrics will be flown by Axiom Exploration Group. The airborne survey will encompass the portion of the claim package covering approximately 10,000 hectares which has not been covered by modern day electromagnetic (EM) survey techniques. The airborne survey aims to precisely locate EM and radiometric anomalies, and aid...

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) — Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment...

Shareholders Urged to Vote for Proven Strategy and Team, Reject Dissident’s Inadequate Plan and Nominees TORONTO, June 11, 2025 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm,” the “Company,” “we” or “us”), a pharmaceutical company specialized in precision-based cannabinoids, today reminded its shareholders that the deadline is approaching to cast your vote for the upcoming Annual and Special Meeting of Shareholders on June 16, 2025 (the “Meeting”). All votes must be received no later than 3:00 p.m. (Eastern time) on Friday, June 13, 2025. We encourage shareholders to please vote using ONLY the GREEN proxy or GREEN voting instruction card and to support each of the director nominees recommended by MediPharm’s Board of Directors (the “Board”) and the other matters being considered at the...